The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain

Journal of Immunology

Volumn 178, Issue 11, 2007, Pages 7132-7138

  Miranda, Luis R ^a   Duval, Mark ^a   Doherty, Heather ^a   Seaman, Michael S ^a   Posner, Marshall R ^a   Cavacini, Lisa A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDASE; GLYCOPROTEIN GP 41; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; MESSENGER RNA; NEUTRALIZING ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING SITE; CHO CELL; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYBRIDOMA; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SEQUENCE HOMOLOGY; VIRUS NEUTRALIZATION;

EID: 34249796660     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.11.7132     Document Type: Article

References (58)

1. Richman, D. D., T. Wrin, S. J. Little, and C. J. Petropoulos. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100: 4144-4149.
2. Wei, X., J. M. Decker, S. Wang, H. Hui, J. C. Kappes, X. Wu, J. F. Salazar-Gonzalez, M. G. Salazar, J. M. Kilby, M. S. Saag, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
3. Kowalski, M., J. Potz, L. Basiripour, T. Dorfman, W. C. Goh, E. Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski. 1987. Functional regions of the envelope glycoprotein of HIV type 1. Science 237: 1351-1355.
4. Kozarsky, K., M. Penman, L. Basiripour, W. Haseltine, J. Sodroski, and M. Krieger. 1989. Glycosylation and processing of HIV-1 envelope protein. J. Acquired Immune Defic. Syndr. 2: 163-169.
5. Pinter, A., W. J. Honnen, S. A. Tilley, C. Bona, H. Zaghouani, M. K. Gomy, and S. Zolla-Pazner. 1989. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol. 63: 2674-2679.
6. Kwong, P. D., R. Wyatt, J. Robinson, R. W. Sweet, J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
7. Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705-711.
8. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
9. Sullivan, N., Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, J. Gershoni, J. Robinson, J. Moore, and J. Sodroski. 1998. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72: 4694-4703.
10. Weissenhorn, W., A. Dessen, S. C. Harrison, J. J. Skehel, and D. C. Wiley. 1997. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
11. Reitter, J. N., R. E. Means, and R. C. Desrosiers. 1998. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4: 679-684.
12. Cardoso, R. M., M. B. Zwick, R. L. Stanfield, R. Kunert, J. M. Binley, H. Katinger, D. R. Burton, and I. A. Wilson. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22: 163-173.
13. Ferrantelli, F., and R. M. Ruprecht. 2002. Neutralizing antibodies against HIV: back in the major leagues. Curr. Opin. Immunol. 14: 495-502.
14. Kessler, J. A. II, P. M. McKenna, E. A. Emini, C. P. Chan, M. D. Patel, S. K. Gupta, G. E. Mark III, C. F. Barbas III, D. R. Burton, and A. J. Conley. 1997. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retroviruses 13: 575-582.
15. Ofek, G., M. Tang, A. Sambor, H. Katinger, J. R. Mascola, R. Wyatt, and P. D. Kwong. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78: 10724-10737.
16. Scanlan, C. N., R. Pantophlet, M. R. Wormald, E. O. Saphire, D. Calarese, R. Stanfield, I. A. Wilson, H. Katinger, R. A. Dwek, D. R. Burton, and P. M. Rudd. 2003. The carbohydrate epitope of the neutralizing anti-HIV-1 antibody 2G12. Adv. Exp. Med. Biol. 535: 205-218.
17. Stiegler, G., and H. Katinger. 2003. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J. Antimicrob. Chemother. 51: 757-759.
18. Zwick, M. B., P. W. Parren, E. O. Saphire, S. Church, M. Wang, J. K. Scott, P. E. Dawson, I. A. Wilson, and D. R. Burton. 2003. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J. Virol. 77: 5863-5876.
19. Amara, R. R., J. M. Smith, S. I. Staprans, D. C. Montefiori, F. Villinger, J. D. Altman, S. P. O'Neil, N. L. Kozyr, Y. Xu, L. S. Wyatt, et al. 2002. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76: 6138-6146.
20. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: 69-74.
21. Amara, R. R., F. Villinger, S. I. Staprans, J. D. Altman, D. C. Montefiori, N. L. Kozyr, Y. Xu, L. S. Wyatt, P. L. Earl, J. G. Herndon, et al. 2002. Different patterns of immune responses but similar control of a simian-human immunode-ficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76: 7625-7631.
22. Barouch, D. H., S. Santra, J. E. Schmitz, M. J. Kuroda, T. M. Fu, W. Wagner, M. Bilska, A. Craiu, X. X. Zheng, G. R. Krivulka, et al. 2000. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
23. Letvin, N. L. 1998. Progress in the development of an HIV-1 vaccine. Science 280: 1875-1880.
24. Montefiori, D. C., K. A. Reimann, M. S. Wyand, K. Manson, M. G. Lewis, R. G. Collman, J. G. Sodroski, D. P. Bolognesi, and N. L. Letvin. 1998. Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1. J. Virol. 72: 3427-3431.
25. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
26. Cavacini, L. A., M. Duval, J. Robinson, and M. R. Posner. 2002. Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS 16: 2409-2417.
27. Moore, J. P., Y. Cao, J. Leu, L. Qin, B. Korber, and D. D. Ho. 1996. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70: 427-444.
28. Cavacini, L. A., C. L. Ernes, J. Power, F. D. Desharaais, M. Duval, D. Montefiori, and M. R. Posner. 1995. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. J. Immunol. 155: 3638-3644.
29. Huang, Y. T., A. Wright, X. Gao, L. Kulick, H. Yan, and M. E. Lamm. 2005. Intraepithelial cell neutralization of HIV-1 replication by IgA. J. Immunol. 174: 4828-4835.
30. Wolbank, S., R. Kunert, G. Stiegler, and H. Katinger. 2003. Characterization of human class-switched polymeric (immunoglobulin M [IgM]] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 77: 4095-4103.
31. Cavacini, L. A., C. L. Ernes, A. V. Wisnewski, J. Power, G. Lewis, D. Montefiori, and M. R. Posner. 1998. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses 14: 1271-1280.
32. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, et al. 2005. Human immunode-ficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79: 10108-10125.
33. McLean, G. R., A. Nakouzi, A. Casadevall, and N. S. Green. 2000. Human and murine immunoglobulin expression vector cassettes. Mol. Immunol. 37: 837-845.
34. Cavacini, L., M. Duval, L. Song, R. Sangster, S. H. Xiang, J. Sodroski, and M. Posner. 2003. Conformational changes in env oligomer induced by an anti-body dependent on the V3 loop base. AIDS 17: 685-689.
35. Mascola, J. R., P. D'Souza, P. Gilbert, B. H. Hahn, N. L. Haigwood, L. Morris, C. J. Petropoulos, V. R. Polonis, M. Sarzotti, and D. C. Montefiori. 2005. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79: 10103-10107.
36. Routier, F., M. Davies, K. Bergemann, and E. Hounsell. 1997. The glycosylation pattern of a humanized IgG1 antibody (D1.3) expressed in CHO cells. Glycoconj. J. 14: 201-207.
37. Sheeley, D., B. Merrill, and L. Taylor. 1997. Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal α-linked galactose. Anal. Biochem. 247: 102-110.
38. Kanda, Y., N. Yamane-Ohnuki, N. Sakai, K. Yamano, R. Nakano, M. Inoue, H. Misaka, S. Iida, M. Wakitani, Y. Konno, et al. 2006. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 94: 680-688.
39. Natsume, A., M. Wakitani, N. Yamane-Ohnuki, E. Shoji-Hosaka, R. Niwa, K. Uchida, M. Satoh, and K. Shitara. 2005. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region. J. Immunol. Methods 306: 93-103.
40. Niwa, R., S. Hatanaka, E. Shoji-Hosaka, M. Sakurada, Y. Kobayashi, A. Uehara, H. Yokoi, K. Nakamura, and K. Shitara. 2004. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin. Cancer Res. 10: 6248-6255.
41. Shields, R., J. Lai, R. Keck, L. O'Connell, K. Hong, Y. Meng, S. Weikert, and L. Presta. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277: 26733-26740.
42. Shinkawa, T., K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, et al. 2003. The absence of fucose but not the presence of galactose or bisecting N- acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278: 3466-3473.
43. Umana, P., J. Jean-Mairet, R. Moudry, H. Amstutz, and J. Bailey. 1999. Engineered glycoforms of an anti-neuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17: 176-180.
44. Laffly, E., and R. Sodoyer. 2005. Monoclonal and recombinant antibodies, 30 years after. Hum. Antibodies 14: 33-55.
45. Holl, V., M. Peressin, T. Decoville, S. Schmidt, S. Zolla-Pazner, A. M. Aubertin, and C. Moog. 2006. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 80: 6177-6181.
46. Roux, K., L. Strelets, O. Brekke, I. Sandlie, and T. Michaelsen. 1998. Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry. J. Immunol. 161: 4083-4090.
47. Scharf, O., H. Golding, L. R. King, N. Eller, D. Frazier, B. Golding, and D. E. Scott. 2001. Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J. Virol. 75: 6558-6565.
48. Cooper, L., L. Schimenti, D. Glass, and N. Greenspan. 1991. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J. Immunol. 146: 2659-2663.
49. Cooper, L., A. Shikhman, D. Glass, D. Kangisser, M. Cunningham, and N. Greenspan. 1993. Role of heavy chain constant domains in antibody-antigen interaction: apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains. J. Immunol. 150: 2231-2242.
50. Roux, K., L. Strelets, and T. Michaelsen. 1997. Flexibility of human IgG sub-classes. J. Immunol. 159: 3372-3382.
51. Choe, H., W. Li, P. L. Wright, N. Vasilieva, M. Venturi, C. C. Huang, C. Grundner, T. Dorfman, M. B. Zwick, L. Wang, et al. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114: 161-170.
52. Gao, J., H. Choe, D. Bota, P. L. Wright, C. Gerard, and N. P. Gerard. 2003. Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin. J. Biol. Chem. 278: 37902-37908.
53. Liu, H., G.-G. Bulseco, and J. Sun. 2006. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol. Lett. 106: 144-153.
54. Mimura, Y., S. Church, R. Ghirlando, P. Ashton, S. Dorig, M. Goodall, J. Lund, and R. Jefferis. 2000. The influence of glycosylation on the thermal stability and effector function expression of human IgGl-Fc: properties of a series of truncated glycoforms. Mol. Immunol. 37: 697-706.
55. Radaev, S., and P. Sun. 2001. Recognition of IgG by Fcγ receptor: the role of Fc glycosylation and the binding of peptide inhibitors. J. Biol. Chem. 276: 16478-16483.
56. Siberil, S., C.-A. Dutertre, C. Boix, E. Bonnin, R. Menez, E. Stura, S. Jorieux, W.-H. Fridman, and J.-L. Teillaud. 2006. Molecular aspects of human FcγR interactions with IgG: functional and therapeutic consequences. Immunol. Lett. 106: 111-118.
57. Koch, M., M. Pancera, P. D. Kwong, P. Kolchinsky, C. Grundner, L. Wang, W. A. Hendrickson, J. Sodroski, and R. Wyatt. 2003. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313: 387-400.
58. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.